Am­gen touts two can­cer study wins with DLL3, Lumakras amid sec­ond-quar­ter earn­ings up­date

Two can­cer drugs suc­ceed­ed in mid- or late-stage clin­i­cal stud­ies, Am­gen said Thurs­day in its sec­ond-quar­ter earn­ings an­nounce­ment.

“Mo­men­tum is build­ing in the pipeline,” Am­gen …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.